Letter : intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
---|---|
Enthalten in: |
Alimentary Pharmacology & Therapeutics - 52(2020), 3, Seite 569-570 |
Beteiligte Personen: |
Garg, Mayur [VerfasserIn] |
---|
BKL: |
---|
Anmerkungen: |
Copyright © 2020 John Wiley & Sons Ltd |
---|
Umfang: |
2 |
---|
doi: |
10.1111/apt.15814 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
WLY002335115 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | WLY002335115 | ||
003 | DE-627 | ||
005 | 20230307114619.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230210s2020 xx |||||o 00| ||und c | ||
024 | 7 | |a 10.1111/apt.15814 |2 doi | |
028 | 5 | 2 | |a APT_APT15814.xml |
035 | |a (DE-627)WLY002335115 | ||
035 | |a (WILEY)APT15814 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.38 |2 bkl | ||
100 | 1 | |a Garg, Mayur |e verfasserin |4 aut | |
245 | 1 | 0 | |a Letter |b intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors |
264 | 1 | |c 2020 | |
300 | |a 2 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Copyright © 2020 John Wiley & Sons Ltd | ||
700 | 1 | |a Royce, Simon G. |4 aut | |
700 | 1 | |a Lubel, John S. |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Alimentary Pharmacology & Therapeutics |g 52(2020), 3, Seite 569-570 |w (DE-627)WLY002324040 |x 13652036 |7 nnns |
773 | 1 | 8 | |g volume:52 |g year:2020 |g number:3 |g pages:569-570 |g extent:2 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_WLY | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
936 | b | k | |a 44.38 |q ASE |
951 | |a AR | ||
952 | |d 52 |j 2020 |e 3 |h 569-570 |g 2 |